Work

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens

Year: 2014

Type: article

Abstract: AlloPBHCT compared to bone marrow transplants have a decreased time to engraftment due to higher levels of CD34+ cells in the graft. However, the correlation of CD34+, CD3+, CD4+, CD8+ and total nucleated cell (TNC) dose with outcomes after alloPBHCT have been inconsistent. We retrospectively analyzed graft cell composition, focusing on conditioning regimen intensity +/- total body irradiation (TBI), in 254 consecutive first alloPBHCT patients from 1/2001 to 9/2012. Patient characteristics are: 58% male, 76% ≥40 years, 56% related/44% unrelated donor, 44% AML, 18% MDS/MPD, 13% ALL, 13% NHL, 12% other diseases, 49% in CR pre-PBHCT.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2013.12.016